(reported by the Company)
No items found
Recce is the creator and world leader of a major new antibiotic type: RECCE antibiotics. These soluble synthetic polymers kill "super bugs" – the worldwide danger, arising from their resistance to conventional antibiotics.
RECCE antibiotics are synthesised by an extremely simple and economic method.
RECCE antibiotics have shown in laboratory tests that they have continued activity against bacteria, even after repeated use, against both Gram-positive and Gram-negative superbugs.
Recce's antibiotics are patented and patent-pending technologies created by a world leading scientist and experienced team.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):||RCE|
|Year of Commencement:||2007|
Suite 7, 3 Brodie Hall Drive
|Key Personnel:||Dr Graham Melrose, Michele Dilizia, James Graham, Ian Brown, Prof Dongke Zhang, Peter Williams|
|Current Period Rank:|
|WA Annual Rank 2016:||51|
FDA granted Recce qualified infectious disease product designation
Started large scale production of its antibiotics at manufacturing facility in Sydney
Started animal testing of its antibitotic
Received positive toxicology results from a dose escalation study of its lead compound RECCE 327, in a mouse with cancer.
Secured funding commitment of up to $6.1m from the Australian Special Opportunity Fund
NOTE: Company News, Milestones and Funding are as collected by Techboard as part of our Monthly Startup Ranking
|Type of capital raise:|